hydroxyurea has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, C | 1 |
| Su, B | 1 |
| Li, Q | 1 |
| Ding, W | 1 |
| Liu, G | 1 |
| Cai, Z | 1 |
| Zhang, F | 1 |
| Lim, D | 1 |
| Feng, Z | 1 |
1 other study available for hydroxyurea and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Histone deacetylase inhibitor 2-hexyl-4-pentynoic acid enhances hydroxyurea therapeutic effect in triple-negative breast cancer cells.
Topics: Cell Cycle; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair; Drug Synergism; Fatty Acids, | 2022 |